{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T03:50:36Z","timestamp":1770954636353,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10822-026-00765-x","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T03:01:05Z","timestamp":1770951665000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of novel pyrazole-isatin and pyrazole-triazole-isatin hybrids as DPP-4 inhibitors"],"prefix":"10.1007","volume":"40","author":[{"given":"Sooraj","family":"Sura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haider","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harish Chandra","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijo","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Nidhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"765_CR1","unstructured":"(2025) International Diabetes Federation. IDF Diabetes Atlas, 11th ed., 2025"},{"key":"765_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"E Dal Canto","year":"2019","unstructured":"Dal Canto E, Ceriello A, Ryd\u00e9n L et al (2019) Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 26:25\u201332. https:\/\/doi.org\/10.1177\/2047487319878371","journal-title":"Eur J Prev Cardiol"},{"issue":"1 13","key":"765_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-29978-y","volume":"13","author":"S Maiti","year":"2023","unstructured":"Maiti S, Akhtar S, Upadhyay AK, Mohanty SK (2023) Socioeconomic inequality in awareness, treatment and control of diabetes among adults in India: evidence from National family health survey of India (NFHS), 2019\u20132021. Sci Rep 2023 13(1 13):1\u201312. https:\/\/doi.org\/10.1038\/s41598-023-29978-y","journal-title":"Sci Rep 2023"},{"key":"765_CR4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ejmech.2018.04.061","volume":"152","author":"N Kerru","year":"2018","unstructured":"Kerru N, Singh-Pillay A, Awolade P, Singh P (2018) Current anti-diabetic agents and their molecular targets: a review. Eur J Med Chem 152:436\u2013488. https:\/\/doi.org\/10.1016\/j.ejmech.2018.04.061","journal-title":"Eur J Med Chem"},{"key":"765_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2174\/156802607780091019","volume":"7","author":"E Sebokova","year":"2007","unstructured":"Sebokova E, Christ A, Boehringer M, Mizrahi J (2007) Dipeptidyl peptidase IV inhibitors: the next generation of new promising therapies for the management of type 2 diabetes. Curr Top Med Chem 7:547\u2013555. https:\/\/doi.org\/10.2174\/156802607780091019","journal-title":"Curr Top Med Chem"},{"key":"765_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"DM Nathan","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 32:193\u2013203. https:\/\/doi.org\/10.2337\/dc08-9025","journal-title":"Diabetes Care"},{"key":"765_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","volume":"3","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3:153\u2013165","journal-title":"Cell Metab"},{"key":"765_CR8","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1517\/14656566.2013.824966","volume":"14","author":"CF Deacon","year":"2013","unstructured":"Deacon CF, Holst JJ (2013) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother 14:2047\u20132058. https:\/\/doi.org\/10.1517\/14656566.2013.824966","journal-title":"Expert Opin Pharmacother"},{"key":"765_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/dom.12591","volume":"18","author":"M Nauck","year":"2016","unstructured":"Nauck M (2016) Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 18:203\u2013216","journal-title":"Diabetes Obes Metab"},{"key":"765_CR10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/ijcp.12361","volume":"68","author":"S Brunton","year":"2014","unstructured":"Brunton S (2014) GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: Is one approach more successful or preferable than the other? Int J Clin Pract 68:557\u2013567","journal-title":"Int J Clin Pract"},{"key":"765_CR11","doi-asserted-by":"crossref","unstructured":"Gallwitz B (2019) Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne) 10","DOI":"10.3389\/fendo.2019.00389"},{"key":"765_CR12","doi-asserted-by":"crossref","unstructured":"Gilbert MP, Pratley RE (2020) GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol (Lausanne) 11","DOI":"10.3389\/fendo.2020.00178"},{"key":"765_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/dom.12319","volume":"17","author":"A Avogaro","year":"2015","unstructured":"Avogaro A, Dardano A, de Kreutzenberg SV, Del Prato S (2015) Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes. Diabetes Obes Metab 17:107\u2013115","journal-title":"Diabetes Obes Metab"},{"key":"765_CR14","doi-asserted-by":"publisher","unstructured":"Bisht P, Bhattacharya A, Pal A et al (2025) Design and synthesis of novel 3,7-dihydro-1H-purine-2,6-diones as DPP-4 inhibitors: an in silico, in vitro and in vivo approach. Eur J Med Chem 283. https:\/\/doi.org\/10.1016\/j.ejmech.2024.117160","DOI":"10.1016\/j.ejmech.2024.117160"},{"key":"765_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0167-0115(99)00089-0","volume":"85","author":"R Mentlein","year":"1999","unstructured":"Mentlein R (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9\u201324. https:\/\/doi.org\/10.1016\/S0167-0115(99)00089-0","journal-title":"Regul Pept"},{"key":"765_CR16","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.2174\/092986709788803114","volume":"16","author":"E Matteucci","year":"2009","unstructured":"Matteucci E, Giampietro O (2009) Dipeptidyl Peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem 16:2943\u20132951. https:\/\/doi.org\/10.2174\/092986709788803114","journal-title":"Curr Med Chem"},{"key":"765_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.peptides.2017.11.023","volume":"100","author":"EE Mulvihill","year":"2018","unstructured":"Mulvihill EE (2018) Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: control of the incretin axis and regulation of postprandial glucose and lipid metabolism. Peptides (NY) 100:158\u2013164. https:\/\/doi.org\/10.1016\/j.peptides.2017.11.023","journal-title":"Peptides (NY)"},{"key":"765_CR18","doi-asserted-by":"crossref","unstructured":"Saini K, Sharma S, Khan Y (2023) DPP-4 inhibitors for treating T2DM - hype or hope? An Analysis based on the current literature. Front Mol Biosci 10","DOI":"10.3389\/fmolb.2023.1130625"},{"key":"765_CR19","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2337\/dc07-0228","volume":"30","author":"DJ Drucker","year":"2007","unstructured":"Drucker DJ (2007) Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes. Diabetes Care 30:1335\u20131343. https:\/\/doi.org\/10.2337\/dc07-0228","journal-title":"Diabetes Care"},{"key":"765_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1517\/17425255.2014.907274","volume":"10","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Athyros VG, Elisaf MS (2014) The Pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opin Drug Metab Toxicol 10:787\u2013812. https:\/\/doi.org\/10.1517\/17425255.2014.907274","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"765_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bbrc.2013.03.010","volume":"434","author":"M Nabeno","year":"2013","unstructured":"Nabeno M, Akahoshi F, Kishida H et al (2013) A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun 434:191\u2013196. https:\/\/doi.org\/10.1016\/j.bbrc.2013.03.010","journal-title":"Biochem Biophys Res Commun"},{"key":"765_CR22","doi-asserted-by":"publisher","first-page":"5860","DOI":"10.3390\/molecules28155860","volume":"28","author":"V Mathur","year":"2023","unstructured":"Mathur V, Alam O, Siddiqui N et al (2023) Insight into structure activity relationship of DPP-4 inhibitors for development of antidiabetic agents. Molecules 28:5860. https:\/\/doi.org\/10.3390\/molecules28155860","journal-title":"Molecules"},{"key":"765_CR23","doi-asserted-by":"publisher","unstructured":"Sever B, Soybir H, G\u00f6rg\u00fcl\u00fc \u015e et al (2020) Pyrazole incorporated new thiosemicarbazones: design, synthesis and investigation of DPP-4 inhibitory effects. Molecules 25. https:\/\/doi.org\/10.3390\/molecules25215003","DOI":"10.3390\/molecules25215003"},{"key":"765_CR24","doi-asserted-by":"publisher","unstructured":"Nidhar M, Khanam S, Sonker P et al (2022) Click inspired novel pyrazole-triazole-persulfonimide & pyrazole-triazole-aryl derivatives; Design, synthesis, DPP-4 inhibitor with potential anti-diabetic agents. Bioorg Chem 120. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105586","DOI":"10.1016\/j.bioorg.2021.105586"},{"key":"765_CR25","doi-asserted-by":"publisher","unstructured":"Chahal S, Rani P, Shweta et al (2024) Pyrano[2,3-c]pyrazole fused spirooxindole-linked 1,2,3-triazoles as antioxidant agents: exploring their utility in the development of antidiabetic drugs via Inhibition of \u03b1-amylase and DPP4 activity. Bioorg Chem 147. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107363","DOI":"10.1016\/j.bioorg.2024.107363"},{"key":"765_CR26","doi-asserted-by":"publisher","unstructured":"Turkan F, Cetin A, Taslimi P, Gul\u00e7in \u0130 (2018) Some pyrazoles derivatives: potent carbonic anhydrase, \u03b1-glycosidase, and cholinesterase enzymes inhibitors. Arch Pharm (Weinheim) 351. https:\/\/doi.org\/10.1002\/ardp.201800200","DOI":"10.1002\/ardp.201800200"},{"key":"765_CR27","doi-asserted-by":"publisher","unstructured":"Naim MJ, Alam O, Alam MJ et al (2018) Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-\u03b3 modulators. Arch Pharm (Weinheim) 351. https:\/\/doi.org\/10.1002\/ardp.201700223","DOI":"10.1002\/ardp.201700223"},{"key":"765_CR28","doi-asserted-by":"publisher","unstructured":"Monisha P, Amalraj S, Gangapriya P et al (2024) One-pot domino synthesis of 1H-isochromene and Pyran carbonitrile from pyrazole aldehyde derivatives as potential anti-diabetic and antioxidant targets. J Mol Struct 1311. https:\/\/doi.org\/10.1016\/j.molstruc.2024.138308","DOI":"10.1016\/j.molstruc.2024.138308"},{"key":"765_CR29","doi-asserted-by":"publisher","unstructured":"Mortada S, Karrouchi K, Hamza EH et al (2024) Synthesis, structural characterizations, in vitro biological evaluation and computational investigations of pyrazole derivatives as potential antidiabetic and antioxidant agents. Sci Rep 14. https:\/\/doi.org\/10.1038\/s41598-024-51290-6","DOI":"10.1038\/s41598-024-51290-6"},{"key":"765_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejmech.2016.04.077","volume":"120","author":"MF Khan","year":"2016","unstructured":"Khan MF, Alam MM, Verma G et al (2016) The therapeutic voyage of pyrazole and its analogs: a review. Eur J Med Chem 120:170\u2013201. https:\/\/doi.org\/10.1016\/j.ejmech.2016.04.077","journal-title":"Eur J Med Chem"},{"key":"765_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/14756366.2016.1180594","volume":"31","author":"HM Faidallah","year":"2016","unstructured":"Faidallah HM, Al-Mohammadi MM, Alamry KA, Khan KA (2016) Synthesis and biological evaluation of Fluoropyrazolesulfonylurea and thiourea derivatives as possible antidiabetic agents. J Enzyme Inhib Med Chem 31:157\u2013163. https:\/\/doi.org\/10.1080\/14756366.2016.1180594","journal-title":"J Enzyme Inhib Med Chem"},{"key":"765_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/07391102.2019.1704885","volume":"39","author":"M Duhan","year":"2021","unstructured":"Duhan M, Singh R, Devi M et al (2021) Synthesis, molecular Docking and QSAR study of thiazole clubbed pyrazole hybrid as \u03b1-amylase inhibitor. J Biomol Struct Dyn 39:91\u2013107. https:\/\/doi.org\/10.1080\/07391102.2019.1704885","journal-title":"J Biomol Struct Dyn"},{"key":"765_CR33","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1039\/C7MD00080D","volume":"8","author":"P Kumar","year":"2017","unstructured":"Kumar P, Duhan M, Kadyan K et al (2017) Synthesis of novel inhibitors of \u03b1-amylase based on the thiazolidine-4-one skeleton containing a pyrazole moiety and their configurational studies. Medchemcomm 8:1468\u20131476. https:\/\/doi.org\/10.1039\/C7MD00080D","journal-title":"Medchemcomm"},{"key":"765_CR34","doi-asserted-by":"publisher","unstructured":"Ritu, Sharma P, Gupta GD, Asati V (2023) Design, synthesis and antidiabetic study of triazole clubbed Indole derivatives as \u03b1-glucosidase inhibitors. Bioorg Chem 139. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106750","DOI":"10.1016\/j.bioorg.2023.106750"},{"key":"765_CR35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5829\/idosi.abr.2013.7.6.76173","volume":"7","author":"JV Rao","year":"2013","unstructured":"Rao JV, Venkateshwarlu E (2013) Evaluation of anti-diabetic and hypolipidemic activity of Isatin derivatives in streptozotocin-nicotinamide induced type II diabetic rats. Adv Biol Res (Rennes) 7:288\u2013295. https:\/\/doi.org\/10.5829\/idosi.abr.2013.7.6.76173","journal-title":"Adv Biol Res (Rennes)"},{"key":"765_CR36","doi-asserted-by":"publisher","unstructured":"Ullah H, Rahim F, Ullah E et al (2023) Synthesis, in vitro \u03b1-glucosidase activity and in Silico molecular docking study of Isatin analogues. Chem Data Collections 43. https:\/\/doi.org\/10.1016\/j.cdc.2022.100987","DOI":"10.1016\/j.cdc.2022.100987"},{"key":"765_CR37","doi-asserted-by":"publisher","unstructured":"Alharthy RD, Zahra SB, Fatima N et al (2023) Synthesis and biological evaluation of novel isatin-hydrazide conjugates as potential antidiabetic agents. J Mol Struct 1288. https:\/\/doi.org\/10.1016\/j.molstruc.2023.135783","DOI":"10.1016\/j.molstruc.2023.135783"},{"key":"765_CR38","doi-asserted-by":"publisher","unstructured":"Solangi M, Kanwal, Khan KM et al (2022) Isatin thiazoles as antidiabetic: synthesis, in vitro enzyme inhibitory activities, kinetics, and in Silico studies. Arch Pharm (Weinheim) 355. https:\/\/doi.org\/10.1002\/ardp.202100481","DOI":"10.1002\/ardp.202100481"},{"key":"765_CR39","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ejmech.2015.02.027","volume":"93","author":"Y Chinthala","year":"2015","unstructured":"Chinthala Y, Thakur S, Tirunagari S et al (2015) Synthesis, Docking and ADMET studies of novel chalcone triazoles for anti-cancer and anti-diabetic activity. Eur J Med Chem 93:564\u2013573. https:\/\/doi.org\/10.1016\/j.ejmech.2015.02.027","journal-title":"Eur J Med Chem"},{"key":"765_CR40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ejmech.2016.09.067","volume":"125","author":"G Wang","year":"2017","unstructured":"Wang G, Peng Z, Wang J et al (2017) Synthesis, in vitro evaluation and molecular Docking studies of novel triazine-triazole derivatives as potential \u03b1-glucosidase inhibitors. Eur J Med Chem 125:423\u2013429. https:\/\/doi.org\/10.1016\/j.ejmech.2016.09.067","journal-title":"Eur J Med Chem"},{"key":"765_CR41","doi-asserted-by":"publisher","unstructured":"Narsimha S, Battula KS, Ravinder M et al (2020) Design, synthesis and biological evaluation of novel 1,2,3-triazole-based Xanthine derivatives as DPP-4 inhibitors. J Chem Sci 132. https:\/\/doi.org\/10.1007\/s12039-020-1760-0","DOI":"10.1007\/s12039-020-1760-0"},{"key":"765_CR42","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1002\/jhet.3951","volume":"57","author":"MAA Mohamed","year":"2020","unstructured":"Mohamed MAA, Abd Allah OA, Bekhit AA et al (2020) Synthesis and antidiabetic activity of novel Triazole derivatives containing amino acids. J Heterocycl Chem 57:2365\u20132378. https:\/\/doi.org\/10.1002\/jhet.3951","journal-title":"J Heterocycl Chem"},{"key":"765_CR43","doi-asserted-by":"publisher","first-page":"142599","DOI":"10.1016\/j.molstruc.2025.142599","volume":"1341","author":"V Kumar","year":"2025","unstructured":"Kumar V, Nidhar M, Sheraj M et al (2025) Designing DPP-4 inhibitors: synthesis, characterization, in silico & in vitro evaluation, and theoretical calculation of flexible compounds linked via ortho Xylyl spacers. J Mol Struct 1341:142599. https:\/\/doi.org\/10.1016\/j.molstruc.2025.142599","journal-title":"J Mol Struct"},{"key":"765_CR44","doi-asserted-by":"publisher","first-page":"16899","DOI":"10.1039\/D3RA00773A","volume":"13","author":"V Kumar","year":"2023","unstructured":"Kumar V, Singh PP, Dwivedi AR et al (2023) Caesium carbonate promoted regioselective O -functionalization of 4,6-diphenylpyrimidin-2(1 H)-ones under mild conditions and mechanistic insight. RSC Adv 13:16899\u201316906. https:\/\/doi.org\/10.1039\/D3RA00773A","journal-title":"RSC Adv"},{"key":"765_CR45","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s11030-022-10577-4","volume":"27","author":"M Nidhar","year":"2023","unstructured":"Nidhar M, Kumar V, Mahapatra A et al (2023) Ligand-based designing of DPP-4 inhibitors via hybridization; synthesis, docking, and biological evaluation of pyridazine-acetohydrazides. Mol Divers 27:2729\u20132740. https:\/\/doi.org\/10.1007\/s11030-022-10577-4","journal-title":"Mol Divers"},{"key":"765_CR46","doi-asserted-by":"publisher","first-page":"111912","DOI":"10.1016\/j.ejmech.2019.111912","volume":"187","author":"B Bindu","year":"2020","unstructured":"Bindu B, Vijayalakshmi S, Manikandan A (2020) Synthesis and discovery of triazolo-pyridazine-6-yl-substituted piperazines as effective anti-diabetic drugs; evaluated over dipeptidyl peptidase-4 Inhibition mechanism and insulinotropic activities. Eur J Med Chem 187:111912. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111912","journal-title":"Eur J Med Chem"},{"key":"765_CR47","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.2337\/diabetes.54.10.2988","volume":"54","author":"GR Lankas","year":"2005","unstructured":"Lankas GR, Leiting B, Roy RS et al (2005) Dipeptidyl peptidase IV Inhibition for the treatment of type 2 diabetes. Diabetes 54:2988\u20132994. https:\/\/doi.org\/10.2337\/diabetes.54.10.2988","journal-title":"Diabetes"},{"key":"765_CR48","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1016\/j.bmc.2012.08.012","volume":"20","author":"T Yoshida","year":"2012","unstructured":"Yoshida T, Akahoshi F, Sakashita H et al (2012) Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem 20:5705\u20135719. https:\/\/doi.org\/10.1016\/j.bmc.2012.08.012","journal-title":"Bioorg Med Chem"},{"key":"765_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3\u201325. 1. Adv Drug Deliv Rev 46:3\u201326. https:\/\/doi.org\/10.1016\/S0169-409X(00)00129-0","journal-title":"Adv Drug Deliv Rev"},{"key":"765_CR50","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0960-894X(00)00172-4","volume":"10","author":"WL Jorgensen","year":"2000","unstructured":"Jorgensen WL, Duffy EM (2000) Prediction of drug solubility from Monte Carlo simulations. Bioorg Med Chem Lett 10:1155\u20131158. https:\/\/doi.org\/10.1016\/S0960-894X(00)00172-4","journal-title":"Bioorg Med Chem Lett"},{"key":"765_CR51","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0169-409X(02)00008-X","volume":"54","author":"WL Jorgensen","year":"2002","unstructured":"Jorgensen WL, Duffy EM (2002) Prediction of drug solubility from structure. Adv Drug Deliv Rev 54:355\u2013366. https:\/\/doi.org\/10.1016\/S0169-409X(02)00008-X","journal-title":"Adv Drug Deliv Rev"},{"key":"765_CR52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1023\/B:PHAM.0000012154.09631.26","volume":"21","author":"JV Turner","year":"2004","unstructured":"Turner JV, Maddalena DJ, Agatonovic-Kustrin S (2004) Bioavailability prediction based on molecular structure for a diverse series of drugs. Pharm Res 21:68\u201382. https:\/\/doi.org\/10.1023\/B:PHAM.0000012154.09631.26","journal-title":"Pharm Res"},{"key":"765_CR53","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2174\/1570163817999200729122753","volume":"18","author":"O Iwaloye","year":"2021","unstructured":"Iwaloye O, Elekofehinti OO, Kikiowo B et al (2021) Discovery of traditional Chinese medicine derived compounds as wild type and mutant plasmodium falciparum dihydrofolate reductase inhibitors: induced fit Docking and ADME studies. Curr Drug Discov Technol 18:554\u2013569. https:\/\/doi.org\/10.2174\/1570163817999200729122753","journal-title":"Curr Drug Discov Technol"},{"key":"765_CR54","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner RA, Banks JL, Murphy RB et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of Docking accuracy. J Med Chem 47:1739\u20131749. https:\/\/doi.org\/10.1021\/jm0306430","journal-title":"J Med Chem"},{"key":"765_CR55","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner RA, Murphy RB, Repasky MP et al (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for Protein\u2009\u2013\u2009Ligand complexes. J Med Chem 49:6177\u20136196. https:\/\/doi.org\/10.1021\/jm051256o","journal-title":"J Med Chem"},{"key":"765_CR56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1093-3263(02)00164-X","volume":"21","author":"CM Venkatachalam","year":"2003","unstructured":"Venkatachalam CM, Jiang X, Oldfield T, Waldman M (2003) LigandFit: a novel method for the shape-directed rapid Docking of ligands to protein active sites. J Mol Graph Model 21:289\u2013307. https:\/\/doi.org\/10.1016\/S1093-3263(02)00164-X","journal-title":"J Mol Graph Model"},{"key":"765_CR57","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s12013-014-9998-0","volume":"70","author":"C Chakraborty","year":"2014","unstructured":"Chakraborty C, Hsu MJ, Agoramoorthy G (2014) Understanding the molecular dynamics of Type-2 diabetes drug target DPP-4 and its interaction with sitagliptin and inhibitor Diprotin-A. Cell Biochem Biophys 70:907\u2013922. https:\/\/doi.org\/10.1007\/s12013-014-9998-0","journal-title":"Cell Biochem Biophys"},{"key":"765_CR58","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2174\/156802607780091064","volume":"7","author":"B Kuhn","year":"2007","unstructured":"Kuhn B, Hennig M, Mattei P (2007) Molecular recognition of ligands in dipeptidyl peptidase IV. Curr Top Med Chem 7:609\u2013620. https:\/\/doi.org\/10.2174\/156802607780091064","journal-title":"Curr Top Med Chem"},{"key":"765_CR59","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3109\/14756366.2014.1002402","volume":"30","author":"YS Watanabe","year":"2015","unstructured":"Watanabe YS, Yasuda Y, Kojima Y et al (2015) Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions. J Enzyme Inhib Med Chem 30:981\u2013988. https:\/\/doi.org\/10.3109\/14756366.2014.1002402","journal-title":"J Enzyme Inhib Med Chem"},{"key":"765_CR60","doi-asserted-by":"publisher","unstructured":"Sudevan ST, Chandran N, Radhakrishnan VV et al (2025) Integrating Atom-Based 3D\u2010QSAR, molecular Docking, and molecular dynamics: a multistep approach for the discovery of potent adenosine A 2 A receptor antagonists. ChemistrySelect 10. https:\/\/doi.org\/10.1002\/slct.202403808","DOI":"10.1002\/slct.202403808"},{"key":"765_CR61","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/ijms17060920","volume":"17","author":"H Meduru","year":"2016","unstructured":"Meduru H, Wang Y-T, Tsai J, Chen Y-C (2016) Finding a potential dipeptidyl peptidase-4 (DPP-4) inhibitor for type-2 diabetes treatment based on molecular docking, pharmacophore generation, and molecular dynamics simulation. Int J Mol Sci 17:920. https:\/\/doi.org\/10.3390\/ijms17060920","journal-title":"Int J Mol Sci"},{"key":"765_CR62","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3390\/pharmaceutics16040483","volume":"16","author":"A Hossain","year":"2024","unstructured":"Hossain A, Rahman ME, Faruqe MO et al (2024) Characterization of plant-derived natural inhibitors of dipeptidyl peptidase-4 as potential antidiabetic agents: a computational study. Pharmaceutics 16:483. https:\/\/doi.org\/10.3390\/pharmaceutics16040483","journal-title":"Pharmaceutics"},{"key":"765_CR63","doi-asserted-by":"publisher","first-page":"e0166275","DOI":"10.1371\/journal.pone.0166275","volume":"11","author":"S Arulmozhiraja","year":"2016","unstructured":"Arulmozhiraja S, Matsuo N, Ishitsubo E et al (2016) Comparative binding analysis of dipeptidyl peptidase IV (DPP-4) with antidiabetic drugs\u2014an Ab initio fragment molecular orbital study. PLoS ONE 11:e0166275. https:\/\/doi.org\/10.1371\/journal.pone.0166275","journal-title":"PLoS ONE"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00765-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-026-00765-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00765-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T03:01:07Z","timestamp":1770951667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-026-00765-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1007\/s10822-026-00765-x","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"63"}}